Optimising care for children with kidney disease

The Lancet

Volumn 389, Issue 10084, 2017, Pages 2084-2086

  Caskey, Fergus J ^a   Morton, Rachael L ^b  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BENCHMARKING; CHILD CARE; CLINICAL PRACTICE; END STAGE RENAL DISEASE; GRAFT SURVIVAL; GROSS NATIONAL PRODUCT; HEALTH CARE; HIGH INCOME COUNTRY; HUMAN; INCIDENCE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LOW INCOME COUNTRY; MORTALITY RATE; MORTALITY RISK; NOTE; PRIORITY JOURNAL; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; SOCIAL STATUS; SURVIVAL RATE; CHILD; CHRONIC KIDNEY FAILURE; EUROPE; REGISTER;

EDETIC ACID;

CHILD; EDETIC ACID; EUROPE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; REGISTRIES; RENAL REPLACEMENT THERAPY;

EID: 85015760527     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30267-2     Document Type: Note

References (11)

1. Chesnaye, NC, Schaefer, F, Bonthuis, M, et al. Mortality risk disparities in children receiving chronic renal replacement therapy for the treatment of end-stage renal disease across Europe: an ESPN-ERA/EDTA Registry analysis. Lancet, 2017 published online March 20. http://dx.doi.org/10.1016/S0140-6736(17)30063-6.
2. Chesnaye, NC, Schaefer, F, Groothoff, JW, et al. Disparities in treatment rates of paediatric end-stage renal disease across Europe: insights from the ESPN/ERA-EDTA registry. Nephrol Dial Transplant 30 (2015), 1377–1385.
3. Caskey, FJ, Kramer, A, Elliott, RF, et al. Global variation in renal replacement therapy for end-stage renal disease. Nephrol Dial Transplant 26 (2011), 2604–2610.
4. Kramer, A, Stel, VS, Caskey, FJ, et al. Exploring the association between macroeconomic indicators and dialysis mortality. Clin J Am Soc Nephrol 7 (2012), 1655–1663.
5. Stevens, K, Valuation of the Child Health Utility 9D Index. Pharmacoeconomics 30 (2012), 729–747.
6. Murray, M, Berwick, DM, Advanced access: reducing waiting and delays in primary care. JAMA 289 (2003), 1035–1040.
7. Harambat, J, van Stralen, KJ, Schaefer, F, et al. Disparities in policies, practices and rates of pediatric kidney transplantation in Europe. Am J Transplant 13 (2013), 2066–2074.
8. Harambat, J, van Stralen, KJ, Verrina, E, Groothoff, JW, Schaefer, F, Jager, KJ, ESPN/ERA-EDTA Registry. Likelihood of children with end-stage kidney disease in Europe to live with a functioning kidney transplant is mainly explained by nonmedical factors. Pediatr Nephrol 29 (2014), 453–459.
9. Gillen, DL, Stehman-Breen, CO, Smith, JM, et al. Survival advantage of pediatric recipients of a first kidney transplant among children awaiting kidney transplantation. Am J Transplant 8 (2008), 2600–2606.
10. O'Neill, J, Tabish, H, Welch, V, et al. Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health. J Clin Epidemiol 67 (2014), 56–64.
11. Morton, RL, Schlackow, I, Mihaylova, B, Staplin, ND, Gray, A, Cass, A, The impact of social disadvantage in moderate-to-severe chronic kidney disease: an equity-focused systematic review. Nephrol Dial Transplant 31 (2016), 46–56.